Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that arises due to a complex array of 50 molecular defects manifesting in dysregulated insulin secretion, impaired insulin action, or both. 51 Since the pathophysiology of T2DM is multifaceted and involves a range of biochemical 52 mechanisms, there is no single therapy can effectively manage all aspects of the disorder (Zaccardi 
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Given the need for more personalised treatment strategies for patients with T2DM and the 92 unique mechanism of action of dapagliflozin and liraglutide, we hypothesised that combining both 93 drugs would provide additive metabolic and neuroprotective outcomes. We chose to administer a 252 DEXA analysis revealed that all treatment groups exhibited significant reduction (37-42% decrease; 253 p<0.05-p<0.001) in percentage fat mass compared to HF controls (Fig. 4A ). No significant 254 differences were noted between DAPA-Lira and liraglutide or dapagliflozin. Similarly, no 255 significant differences were observed in lean mass for any groups tested (Fig. 4B ). Compared with 256 HF controls, all treatments significantly decreased triglycerides (p<0.5-p<0.001; Fig. 4C ). DAPA-257 Lira reduced triglycerides (71-87% decrease; p<0.01-p<0.001; Fig. 4C ) to a greater extent than 258 either liraglutide or dapagliflozin alone. No significant differences between HF groups in terms of 259 total cholesterol was observed (Fig. 4D ). 262 Administration of DAPA-Lira and dapagliflozin resulted in a significant reduction in inguinal 263 adipose weight (p<0.05; Fig. 5A ). Liver and pancreatic weights were not significantly different in 264 Page 11 of 40 12 any of the HF groups ( Fig. 5B and 5C ). Total plasma GLP-1 concentrations were significantly 265 increased in all treatment groups (p<0.001) compared to HF controls with DAPA-Lira group 266 displaying increased levels of total GLP-1 (12-18% increase; p<0.01-p<0.001) compared to 267 liraglutide or dapagliflozin alone (Fig. 5D ). No significant differences were noted in ALT levels in 268 HF mice (Fig. 5E ). Both dapagliflozin and DAPA-Lira treatment groups displayed significantly 269 elevated (1.0-fold; p<0.01-p<0.001) plasma IL-6 levels compared to HF controls (Fig. 5F) . 270 Liraglutide only treated mice displayed reduced (48% decrease; p<0.001) IL-6 levels compared to 271 DAPA-Lira treatment (Fig. 5F ). All treatment groups resulted in significant reduction (33-43% 272 decrease; p<0.05) in corticosterone concentrations compared to HF controls (Fig. 5G ).
Effects of DAPA-Lira on body composition and lipids

Effects of DAPA-Lira on terminal organ weight, hormones and biomarkers
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Effects of DAPA-Lira in novel object recognition task 275 During test trial, no significant difference was noted in the recognition index (RI) for the HF group 276 indicating that they could not discriminate between novel and familiar object thereby exhibiting 277 impaired cognition (Fig. 6A ). All treatment groups and lean control group displayed significantly 278 increased RI (1.1-1.3-fold; p<0.01-p<0.001) when exposed to novel object compared to HF controls, 279 thus highlighting preference to explore novel versus familiar object ( Fig. 6B-6F ). Open field 280 assessment revealed no effect of any treatments on motor activity (speed and path length), anxiety 281 (grooming events) and exploration (rearing events) (data not shown). As shown in Fig. 7A , beta cell area was significantly increased (p<0.05) in liraglutide treated mice. 286 Mice treated with dapagliflozin alone exhibited marked increase (p<0.01) in alpha cell area 287 compared to HF controls (Fig. 7D) . In contrast, DAPA-Lira or liraglutide alone did not affect alpha 288 Page 12 of 40 13 cell area (Fig. 7D ). Islets of HF mice exhibited substantial staining for IL-6 in beta cells and GLP-1 289 in alpha cells with no appreciable differences between various treatment groups (images not shown). 290 Both DAPA-Lira and liraglutide markedly increased (1.4-1.6 fold; p<0.05) pancreatic insulin 291 content compared to HF controls (Fig. 7B ). Liraglutide treatment also significantly decreased (23% 292 reduction; p<0.001) glucagon content while both DAPA-Lira and dapagliflozin led to significant 293 increases compared to HF controls (21-28% increase; p<0.01-p<0.001; Fig. 7E ). A similar pattern to 294 changes in pancreatic insulin and glucagon content were observed in pancreatic mRNA expression 295 of insulin and glucagon ( Fig. 7C and 7F ). 298 Representative micrographs of doublecortin and synaptophysin staining are shown in Fig. 8A-8E . 299 Mice treated with DAPA-Lira, dapagliflozin or liraglutide displayed increased number of immature 300 neurons in the dentate gyrus (44-69% increase; p<0.01-p<0.001; Fig. 8F ) compared to HF controls 301 as indicated by increased number of DCX-positive cells. Significantly higher levels of 302 synaptophysin expression were demonstrated in all treatment groups in stratum oriens layer (88-303 113% increase; p<0.01; Fig. 8J ) compared to HF controls. DAPA-Lira treatment also improved 304 synaptophysin expression in stratum pyramidale layer (50% increase; p<0.05; Fig. 8I ), though no 305 differences in polymorph layer (Fig. 8G ) and stratum radiatum (Fig. 8H) were observed. with high fat feeding to inflict sub-lethal damage to beta cells which when combined with high fat 320 feeding gave a more rapid and pronounced diabetes phenotype with elevation in blood glucose 321 concentrations. SGLT2 inhibitors act by reabsorbing glucose so it is useful to study therapeutic 322 effects when glucose levels are significantly raised. In contrast to liraglutide, DAPA-Lira 323 combination therapy over 28 days did not affect energy intake. This is an important observation as 324 several studies suggested that energy intake is increased following SGLT2 inhibitor therapy dapagliflozin, which would be beneficial in a longer-term treatment regimen. We did not see tight 398 correlation between the various parameters (percentage islet cells, hormone content and basal 399 hormone levels) because many different factors influence these parameters. For example, if cell 400 synthesizes hormone it is not just leaked out into the blood but is stored in vesicles that are regulated 401 on minute-to-minute basis by prevailing blood glucose plus myriad of other factors. 402 We and others have previously shown that high fat feeding in rodents causes detrimental 
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Effects of DAPA-Lira on islet morphology, pancreatic hormone content and mRNA gene
Effects of DAPA-Lira on neurogenesis and synaptic density
